New targeted drug effectively dissolves blood clots
The new drug is safe for intravenous injection and can dissolve clots up to 4000 times more efficiently than ordinary enzyme-based drugs.
Scientists from ITMO University in co-operation with Mariinsky Hospital in Saint Petersburg have developed a magnetically controlled drug that can be condensed on a blood clot by means of a magnetic field. The new drug is safe for intravenous injection and can dissolve clots up to 4000 times more efficiently than ordinary enzyme-based drugs. The new study will also help reduce drug dosage, thus avoiding numerous side effects. The results of the research were published in Scientific Reports.
The challenge is that thrombolytic drugs do not target the clot, but rather spread over the whole circulatory system. The organism begins to block a foreign enzyme, quickly diminishing its activity. Therefore, the drugs are injected in knock-out doses in hope that at least a small portion will reach the blood clot on time. "Now we are using a sledge-hammer to crack a nut", says Ivan Dudanov, head of the regional cardiovascular center of Mariinsky hospital. "Dissolving a little blood clot that blocked a vessel of only 1-2 mm in diameter, thrombolytic drugs negatively affect the entire network of blood vessels. To change the situation, we decided to develop a method of targeted drug delivery that would allow us to considerably reduce the dosage and ensure that the whole therapeutic effect is focused on the clot."
The scientists produced a composite material, which can deliver thrombolytic enzymes in a safe and targeted manner. The new material is composed of a porous magnetite framework and molecules of urokinase — an enzyme frequently used in medicine as a thrombolytic agent. The composite can be used to create thrombolytic coating for artificial blood vessels and stable injectable solutions made of nanosized particles that can be easily localized near the clot by means of an external magnetic field.
Importantly, the magnetite framework also protects enzymes from various inhibitors that are present in the blood and can deactivate thrombolytic medications. Andrey Drozdov, first author of the study and researcher at the Laboratory of Solution Chemistry of Advanced Materials and Technologies notes: "Usually, in order to achieve a prolonged effect for such drugs, the enzyme is placed inside a polymeric matrix. The enzyme is then gradually released from the matrix and eventually looses all activity. We, on the other hand, experimentally demonstrated that enzymes protected using our approach do not lose therapeutic properties over extended periods of time and even after repeated use. The rate, at which the new drug can dissolve the clot outperforms unprotected enzymes by about 4000 times."
The material is potentially safe for humans, because it is made of components that already have permission for intravenous injection. According to Professor Dudanov, future drugs based on the new composite could be used not only for thrombosis treatment, but also for its prevention. Circulating in the blood even in small amounts, the enzyme can gently clean the vessels and will stay active for a very long time until it is naturally excreted through liver like an ordinary metabolite.
This work became a logical continuation of earlier studies devoted to the enzyme entrapment into sol-gel magnetite matrix and the production of magnetically controlled bioactive systems.
"In this phase of our project, we have demonstrated how the concept we developed works for more specific objects. We prepared a thrombolytic colloid and tested its effects on an artificial blood clots obtained from plasma and blood of humans, and thrombus extracted from patients. The results may soon allow us to try out the new thrombolytic system on mammals. Now we are preparing for preclinical studies," concludes Vladimir Vinogradov, head of the Laboratory of Solution Chemistry of Advanced Materials and Technologies.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance